1. Home
  2. GDTC vs BOWN Comparison

GDTC vs BOWN Comparison

Compare GDTC & BOWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GDTC
  • BOWN
  • Stock Information
  • Founded
  • GDTC 2018
  • BOWN 2023
  • Country
  • GDTC Singapore
  • BOWN United States
  • Employees
  • GDTC N/A
  • BOWN N/A
  • Industry
  • GDTC Biotechnology: Pharmaceutical Preparations
  • BOWN
  • Sector
  • GDTC Health Care
  • BOWN
  • Exchange
  • GDTC Nasdaq
  • BOWN Nasdaq
  • Market Cap
  • GDTC 28.0M
  • BOWN 28.5M
  • IPO Year
  • GDTC 2023
  • BOWN 2023
  • Fundamental
  • Price
  • GDTC $2.11
  • BOWN $9.20
  • Analyst Decision
  • GDTC Buy
  • BOWN
  • Analyst Count
  • GDTC 1
  • BOWN 0
  • Target Price
  • GDTC $5.00
  • BOWN N/A
  • AVG Volume (30 Days)
  • GDTC 6.7K
  • BOWN 2.5K
  • Earning Date
  • GDTC 01-01-0001
  • BOWN 01-01-0001
  • Dividend Yield
  • GDTC N/A
  • BOWN N/A
  • EPS Growth
  • GDTC N/A
  • BOWN N/A
  • EPS
  • GDTC N/A
  • BOWN 0.02
  • Revenue
  • GDTC $368,838.00
  • BOWN N/A
  • Revenue This Year
  • GDTC $5.37
  • BOWN N/A
  • Revenue Next Year
  • GDTC N/A
  • BOWN N/A
  • P/E Ratio
  • GDTC N/A
  • BOWN $201.47
  • Revenue Growth
  • GDTC N/A
  • BOWN N/A
  • 52 Week Low
  • GDTC $1.20
  • BOWN $2.71
  • 52 Week High
  • GDTC $4.05
  • BOWN $19.77
  • Technical
  • Relative Strength Index (RSI)
  • GDTC 39.85
  • BOWN 43.24
  • Support Level
  • GDTC $2.09
  • BOWN $9.14
  • Resistance Level
  • GDTC $2.22
  • BOWN $10.20
  • Average True Range (ATR)
  • GDTC 0.09
  • BOWN 0.39
  • MACD
  • GDTC -0.01
  • BOWN -0.03
  • Stochastic Oscillator
  • GDTC 0.00
  • BOWN 39.35

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

About BOWN Bowen Acquisition Corp

Bowen Acquisition Corp is a blank check company.

Share on Social Networks: